(ARWR) Arrowhead Pharmaceuticals - Overview
Stock: Plozasiran, Zodasiran, ARO-DIMER-PA, ARO-PNPLA3, ARO-INHBE
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 70.5% |
| Relative Tail Risk | -10.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.02 |
| Alpha | 220.26 |
| Character TTM | |
|---|---|
| Beta | 1.718 |
| Beta Downside | 1.484 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.86% |
| CAGR/Max DD | 0.31 |
Description: ARWR Arrowhead Pharmaceuticals January 13, 2026
Arrowhead Pharmaceuticals (NASDAQ:ARWR) focuses on RNA-interference (RNAi) therapeutics for hard-to-treat diseases in the U.S. Its lead pipeline features Plozasiran (apoC-III) and Zodasiran (ANGPTL3), both in Phase 3 trials, alongside a suite of early-stage RNAi candidates targeting metabolic and inflammatory pathways (e.g., ARO-DIMER-PA, ARO-PNPLA3, ARO-INHBE, ARO-ALK7, ARO-RAGE, ARO-MAPT, ARO-C3, ARO-CFB). The company leverages partnership agreements with GlaxoSmithKline, Takeda, Amgen, and Sarepta to co-develop and commercialize its assets.
As of the latest 10-Q, Arrowhead reported a cash position of roughly $560 million, providing a runway of about 18 months at current burn rates; its market capitalization hovers near $3 billion, and recent Phase 3 interim data for Plozasiran showed a 30 % reduction in triglycerides, a key efficacy signal that could unlock a multi-billion-dollar market if FDA approval is achieved.
The RNAi sector is experiencing rapid growth, driven by the FDA’s expanding acceptance of gene-silencing modalities (e.g., approvals of Alnylam’s Onpattro and GIVLAARI) and a projected CAGR of 20 % through 2030, which underpins strong investor interest and higher valuation multiples for companies with late-stage pipelines.
For a deeper dive into Arrowhead’s valuation dynamics and scenario analysis, you might explore the detailed model on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: -1.63m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 64.34 > 1.0 |
| NWC/Revenue: 91.04% < 20% (prev 2182 %; Δ -2091 % < -1%) |
| CFO/TA 0.13 > 3% & CFO 179.6m > Net Income -1.63m |
| Net Debt (166.2m) to EBITDA (100.6m): 1.65 < 3 |
| Current Ratio: 4.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (135.7m) vs 12m ago 11.24% < -2% |
| Gross Margin: 97.89% > 18% (prev 0.0%; Δ 9789 % > 0.5%) |
| Asset Turnover: 65.70% > 50% (prev 2.38%; Δ 63.32% > 0%) |
| Interest Coverage Ratio: 0.93 > 6 (EBITDA TTM 100.6m / Interest Expense TTM 89.4m) |
Altman Z'' -1.75
| A: 0.55 (Total Current Assets 950.6m - Total Current Liabilities 195.5m) / Total Assets 1.39b |
| B: -1.17 (Retained Earnings -1.63b / Total Assets 1.39b) |
| C: 0.07 (EBIT TTM 83.1m / Avg Total Assets 1.26b) |
| D: -1.85 (Book Value of Equity -1.63b / Total Liabilities 881.9m) |
| Altman-Z'' Score: -1.75 = D |
What is the price of ARWR shares?
Over the past week, the price has changed by -0.68%, over one month by -0.72%, over three months by +71.56% and over the past year by +246.47%.
Is ARWR a buy, sell or hold?
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARWR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.9 | 18.5% |
| Analysts Target Price | 81.9 | 18.5% |
| ValueRay Target Price | 74.3 | 7.5% |
ARWR Fundamental Data Overview January 25, 2026
P/S = 11.2694
P/B = 20.8192
P/EG = -1.32
Revenue TTM = 829.4m USD
EBIT TTM = 83.1m USD
EBITDA TTM = 100.6m USD
Long Term Debt = 214.9m USD (from longTermDebt, last quarter)
Short Term Debt = 40.0m USD (from shortLongTermDebt, last quarter)
Debt = 733.7m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 166.2m USD (from netDebt column, last quarter)
Enterprise Value = 9.99b USD (9.35b + Debt 733.7m - CCE 88.7m)
Interest Coverage Ratio = 0.93 (Ebit TTM 83.1m / Interest Expense TTM 89.4m)
EV/FCF = 63.69x (Enterprise Value 9.99b / FCF TTM 156.9m)
FCF Yield = 1.57% (FCF TTM 156.9m / Enterprise Value 9.99b)
FCF Margin = 18.91% (FCF TTM 156.9m / Revenue TTM 829.4m)
Net Margin = -0.20% (Net Income TTM -1.63m / Revenue TTM 829.4m)
Gross Margin = 97.89% ((Revenue TTM 829.4m - Cost of Revenue TTM 17.5m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 77.59%)
Tobins Q-Ratio = 7.21 (Enterprise Value 9.99b / Total Assets 1.39b)
Interest Expense / Debt = 2.96% (Interest Expense 21.7m / Debt 733.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = 65.6m (EBIT 83.1m * (1 - 21.00%))
Current Ratio = 4.86 (Total Current Assets 950.6m / Total Current Liabilities 195.5m)
Debt / Equity = 1.57 (Debt 733.7m / totalStockholderEquity, last quarter 466.1m)
Debt / EBITDA = 1.65 (Net Debt 166.2m / EBITDA 100.6m)
Debt / FCF = 1.06 (Net Debt 166.2m / FCF TTM 156.9m)
Total Stockholder Equity = 431.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.13% (Net Income -1.63m / Total Assets 1.39b)
RoE = -0.38% (Net Income TTM -1.63m / Total Stockholder Equity 431.1m)
RoCE = 12.86% (EBIT 83.1m / Capital Employed (Equity 431.1m + L.T.Debt 214.9m))
RoIC = 9.04% (NOPAT 65.6m / Invested Capital 725.7m)
WACC = 11.53% (E(9.35b)/V(10.08b) * Re(12.25%) + D(733.7m)/V(10.08b) * Rd(2.96%) * (1-Tc(0.21)))
Discount Rate = 12.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.40%
[DCF Debug] Terminal Value 70.67% ; FCFF base≈156.9m ; Y1≈193.5m ; Y5≈329.6m
Fair Price DCF = 21.93 (EV 3.22b - Net Debt 166.2m = Equity 3.06b / Shares 139.4m; r=11.53% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 3.19 | EPS CAGR: -6.28% | SUE: -0.09 | # QB: 0
Revenue Correlation: -9.36 | Revenue CAGR: 81.49% | SUE: 0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.95 | Chg30d=+0.132 | Revisions Net=+1 | Analysts=9
EPS current Year (2026-09-30): EPS=-3.30 | Chg30d=-0.137 | Revisions Net=-3 | Growth EPS=-32909.1% | Growth Revenue=-51.8%
EPS next Year (2027-09-30): EPS=-4.39 | Chg30d=+0.139 | Revisions Net=+0 | Growth EPS=-32.9% | Growth Revenue=-27.2%